Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a class of medicines, which it refers to as Bicycles. Co.'s programs are focused on oncology indications with unmet medical need. Co.'s primary product candidate, BT1718, is a Bicycle Toxin Conjugate (BTC) which target tumors that express Membrane Type 1 matrix metalloprotease. Co. is also evaluating BT5528, a BTC targeting Ephrin type-A receptor 2, and conducting Investigational New Drug application enabling activities for BT8009, a BTC targeting Nectin-4. Co.'s discovery pipeline in oncology includes Bicycle-based systemic immune cell agonists and Bicycle tumor-targeted immune cell agonists (TICAs). The BCYC stock yearly return is shown above.
The yearly return on the BCYC stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the BCYC annual return calculation with any dividends reinvested as applicable (on ex-dates).
|